More tools:Markets·Screener·Research·Chat

GeoVax Labs, Inc. New (GOVX) Financial Statements

GeoVax Labs, Inc. New
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S6ZC26
XNAS · usd
0.47▼ 0.02 (-3.13%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close0.48
Day's Range0.46 – 0.50
52-Week Range0.12 – 4.40
Volume512.0K
Avg Volume884.0K
Share Statistics
Shares Outstanding
Employees19
ExchangeXNAS
Listed1995-02-01
Share count as of July 27, 2026
Loading Income Statement…
Key questions about GeoVax Labs, Inc. New (GOVX)
What is GeoVax Labs, Inc. New's Market Cap?
GeoVax Labs, Inc. New's Market Cap is $3.4M, based on as-reported figures from SEC (XBRL) filings.
What is GeoVax Labs, Inc. New's Enterprise Value?
GeoVax Labs, Inc. New's Enterprise Value is $305.4K, based on as-reported figures from SEC (XBRL) filings.
What is GeoVax Labs, Inc. New's EV / EBITDA?
GeoVax Labs, Inc. New's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is GeoVax Labs, Inc. New's Revenue (TTM)?
GeoVax Labs, Inc. New's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is GeoVax Labs, Inc. New's Net Income (TTM)?
GeoVax Labs, Inc. New's Net Income (TTM) is -$20.4M, based on as-reported figures from SEC (XBRL) filings.
What is GeoVax Labs, Inc. New's EBITDA?
GeoVax Labs, Inc. New's EBITDA is -$20.5M, based on as-reported figures from SEC (XBRL) filings.
What is GeoVax Labs, Inc. New's Diluted EPS (TTM)?
GeoVax Labs, Inc. New's Diluted EPS (TTM) is -2.77, based on as-reported figures from SEC (XBRL) filings.
What is GeoVax Labs, Inc. New's Net Debt?
GeoVax Labs, Inc. New's Net Debt is -$3.1M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue from government contract
YoY growth-100.0%-100.0%-100.0%-100.0%
Research and development
General and administrative
Total operating expenses
% of revenue————
Loss from operations
% of revenue————
Interest income
Net loss
% of revenue————
Net loss per common share (in dollars per share)—